Skip to main content

linifanib

Generic: Linifanib

linifanib: 6 clinical trials tracked.

linifanib evidence translation

What we can confirm

6 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about linifanib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (6)

A Pharmacokinetic Study to Evaluate the Effect of Food on the Oral Bioavailability and Effect of Diurnal Variation on the Pharmacokinetics of ABT-869

NCT00733187Registry updated 2017-11-21·Phase 1
Completed

Primary endpoint: Pharmacokinetic

Interventionalopen34 enrolledStarted 2009-02Completion 2012-06AbbVie (prior sponsor, Abbott)

An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer

NCT00707889Registry updated 2013-05-15·Phase 2
Completed

Primary endpoint: Progression-free survival

InterventionalRandomizedopen159 enrolledStarted 2008-10Completion 2012-0546 sites · Australia, Belgium, Brazil, Canada…AbbVie (prior sponsor, Abbott)

A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic Breast Cancer

NCT00645177Registry updated 2013-01-29·Phase 2
Completed

Primary endpoint: Progression-free survival

InterventionalRandomizeddouble10 enrolledStarted 2008-07Completion 2009-123 sites · Mexico, United StatesAbbVie (prior sponsor, Abbott)

A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment

NCT00716534Registry updated 2013-04-29·Phase 2
Completed

Primary endpoint: Progression Free Survival (PFS)

InterventionalRandomizeddouble145 enrolledStarted 2008-06Completion 2012-0437 sites · Australia, Brazil, Czechia, Russia…AbbVie (prior sponsor, Abbott)

An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

NCT00517920Registry updated 2013-01-04·Phase 2
Completed

Primary endpoint: Progression-Free Rate

Interventionalopen44 enrolledStarted 2007-09Completion 2012-066 sites · Canada, Singapore, Taiwan, United StatesAbbVie (prior sponsor, Abbott)

An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib

NCT00486538Registry updated 2013-01-04·Phase 2
Completed

Primary endpoint: Objective Response Rate

Interventionalopen53 enrolledStarted 2007-06Completion 2012-0613 sites · Canada, United StatesAbbVie (prior sponsor, Abbott)